Europe - FRA:H6D0 - GB00BMX86B70 - Common Stock
The current stock price of H6D0.DE is 4.029 EUR. In the past month the price increased by 5.66%. In the past year, price decreased by -10.47%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1LLY.MI | ELI LILLY & CO | 39.04 | 703.22B | ||
| LLY.DE | ELI LILLY & CO | 39.03 | 703.03B | ||
| ZEG.DE | ASTRAZENECA PLC | 18.58 | 440.12B | ||
| JNJ.DE | JOHNSON & JOHNSON | 18.19 | 393.33B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 17.76 | 384.13B | ||
| RHO.DE | ROCHE HOLDING AG-BR | 13.86 | 237.60B | ||
| SNW.DE | SANOFI | 11.54 | 213.75B | ||
| SAN.PA | SANOFI | 11.53 | 213.49B | ||
| 1SAN.MI | SANOFI | 11.48 | 212.63B | ||
| NOT.DE | NOVARTIS AG-REG | 13.87 | 207.52B | ||
| 1NOVN.MI | NOVARTIS AG-REG | 13.84 | 207.14B | ||
| NOV.DE | NOVO NORDISK A/S-B | 12.75 | 189.20B |
Haleon Plc engages in the provision of personal healthcare products. The company is headquartered in Weybridge, Surrey and currently employs 24,000 full-time employees. The company went IPO on 2022-07-18. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.
HALEON PLC
Building 5, First Floor, The Heights
Weybridge SURREY GB
Employees: 24000
Phone: 441932822000
Haleon Plc engages in the provision of personal healthcare products. The company is headquartered in Weybridge, Surrey and currently employs 24,000 full-time employees. The company went IPO on 2022-07-18. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.
The current stock price of H6D0.DE is 4.029 EUR. The price increased by 1.23% in the last trading session.
HALEON PLC (H6D0.DE) has a dividend yield of 1.94%. The yearly dividend amount is currently 0.07.
H6D0.DE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
ChartMill assigns a technical rating of 1 / 10 to H6D0.DE. When comparing the yearly performance of all stocks, H6D0.DE is a bad performer in the overall market: 86.73% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to H6D0.DE. There are concerns on the financial health of H6D0.DE while its profitability can be described as average.
Over the last trailing twelve months H6D0.DE reported a non-GAAP Earnings per Share(EPS) of 0.2. The EPS increased by 6.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.84% | ||
| ROA | 4.2% | ||
| ROE | 8.92% | ||
| Debt/Equity | 0.53 |
26 analysts have analysed H6D0.DE and the average price target is 4.9 EUR. This implies a price increase of 21.67% is expected in the next year compared to the current price of 4.029.
For the next year, analysts expect an EPS growth of 5.23% and a revenue growth -1.7% for H6D0.DE